• Boston Scientific (NYSE:BSX) is continuing with acquisitions, including Penumbra, to deepen its presence in key therapeutic areas.
• The company is focusing on Pulmonary Field Ablation and Left Atrial Appendage Closure as areas with strong potential heading into 2026.
• Recent moves are intended to improve operational efficiency and support higher revenue growth and market share.

Boston Scientific enters this news with shares at $91.62 and a long-term return of 133.4% over five years, alongside a 90.5% return over three years. The stock shows a 3.3% decline year to date and an 11.5% decline over the past year, which frames investor expectations around how these acquisitions and therapies may support the next phase of the company’s development.

For investors watching NYSE:BSX, a key consideration is how efficiently the company can integrate Penumbra and scale its Pulmonary Field Ablation and Left Atrial Appendage Closure offerings. These business moves are central to the story for 2026 and may influence how the market views Boston Scientific's ability to expand its portfolio and strengthen its market position.

Stay updated on the most important news stories for Boston Scientific by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Boston Scientific.

Quick Assessment

• ❌ Price vs Analyst Target: At US$91.62 versus a US$124.03 consensus target, the shares sit about 26% below where analysts see value.
• ❌ Simply Wall St Valuation: The stock is flagged as trading 32.6% above estimated fair value, which points to an overvalued status.
• ❌ Recent Momentum: A 30 day return of 3.3% decline shows recent pressure on the share price despite the acquisition story.

Check out Simply Wall St's in depth valuation analysis for Boston Scientific.

Key Considerations

• 📊 The Penumbra deal and focus on Pulmonary Field Ablation and Left Atrial Appendage Closure support Boston Scientific's push in higher growth therapies heading into 2026.
• 📊 Keep an eye on integration execution, revenue contribution from the new therapies, and whether the 48.7x P/E and 38.1x forward P/E stay supported by earnings delivery.
• ⚠️ The company carries a high level of debt, so investors may want to watch how acquisition spending and future cash flows affect balance sheet flexibility.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Boston Scientific analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.